ResMed Inc. Common Stock (RMD)
231.48
-1.62 (-0.69%)
ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions
The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape.

Since September 2024, ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short of the S&P 500’s 6.2% gain during that period.
Via StockStory · March 4, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom (NASDAQDXCM).
Via StockStory · February 27, 2025

Via Benzinga · February 26, 2025

Medical tech company Masimo (NASDAQMASI)
will be reporting earnings tomorrow after the bell. Here’s what to look for.
Via StockStory · February 24, 2025

Insulin delivery company Insulet Corporation (NASDAQPODD) will be announcing earnings results tomorrow after market close. Here’s what to expect.
Via StockStory · February 19, 2025

Medical technology company iRhythm Technologies (NASDAQIRTC)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
Via StockStory · February 19, 2025

Medical device company DexCom (NASDAQDXCM)
will be reporting earnings tomorrow after the bell. Here’s what investors should know.
Via StockStory · February 12, 2025

ResMed also boasts a 93 Composite Rating. The best growth stocks often have a 90 or higher Composite as they begin their biggest runs.
Via Investor's Business Daily · February 11, 2025

Shares of SoundHound AI are trading within a range. Some traders will get involved if the stock breaks out or breaks down.
Via Benzinga · February 4, 2025

If shares of ResMed (RMD) reach support, potential buyers may start to outbid each other. This could force the shares into an uptrend.
Via Benzinga · February 3, 2025

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.
Via Talk Markets · February 2, 2025

Medical device company ResMed (NYSERMD) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above analysts’ consensus estimates.
Via StockStory · January 31, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · January 31, 2025

Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below.
Via Chartmill · January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · January 31, 2025

Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.
Via Chartmill · January 31, 2025

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.
Via The Motley Fool · January 30, 2025

Major stock indices have completed their recovery following Monday's sharp drop, buoyed by tech stocks rallying on the back of solid earnings and positive macroeconomic data. The S&P 500 index stands at 6,118 points at midday trading in New York, not far from the all-time high of 6,128 points reached last Friday.
Via Benzinga · January 31, 2025

The company easily beat earnings expectations, while sales were narrowly above.
Via Investor's Business Daily · January 30, 2025

Wall Street is struggling to find risk-on momentum, with major indexes stuck near the flatline at midday as investors assess the latest earnings reports from mega-cap tech stocks and weaker-than-expected U.S.
Via Benzinga · January 30, 2025

A fundamental analysis of (NYSERMD): Why Quality-Oriented Investors Should Consider NYSE:RMD.
Via Chartmill · January 28, 2025